Back to FlashcardsNursing / Simmons NURP 502 Exam 1 COPD Management
How do you track disease progression and reassess severity?
Tap or swipe ↕ to flip
Swipe ←→Navigate
1/19
Key Terms
Term
Definition
How do you track disease progression and reassess severity?
• MMRC breathlessness assessment • Spirometry (perform regularly)
What is the treatment for this stage? Stage 4: Very Severe
• Active reduction of risk factors • Flu vaccine • SABA • 1 or more LABAs • Pulmonary Rehab • ICS if repeated exacerbations • O2 therapy if chronic re...
Upon initial diagnosis, what is the nonpharm treatment plan?
• Smoking cessation • Referral for pulmonary rehab • Regular exercise • Phsych eval for eating disorder, depression • Nutritional eval • Patient educa...
Which comorbidity should especially be monitored?
Cardiovascular
What are the pharm options for COPD?
• SABAs (sympathomimetics) • Anticholinergics • LABAs (alone or combined with anticholinergic) • ICS • Systemic steroids • Methylxanthines (Theophylli...
Which type of COPD patients benefit little from mucolytic agents like Mucinex?
Stable patients benefit very little. More benefit with proper hydration (6-8 8-ounce glasses of water).
Related Flashcard Decks
| Term | Definition |
|---|---|
How do you track disease progression and reassess severity? | • MMRC breathlessness assessment • Spirometry (perform regularly) |
What is the treatment for this stage? Stage 4: Very Severe | • Active reduction of risk factors • Flu vaccine • SABA • 1 or more LABAs • Pulmonary Rehab • ICS if repeated exacerbations • O2 therapy if chronic respiratory failure |
Upon initial diagnosis, what is the nonpharm treatment plan? | • Smoking cessation • Referral for pulmonary rehab • Regular exercise • Phsych eval for eating disorder, depression • Nutritional eval • Patient education on COPD and smoking cessation |
Which comorbidity should especially be monitored? | Cardiovascular |
What are the pharm options for COPD? | • SABAs (sympathomimetics) • Anticholinergics • LABAs (alone or combined with anticholinergic) • ICS • Systemic steroids • Methylxanthines (Theophylline) |
Which type of COPD patients benefit little from mucolytic agents like Mucinex? | Stable patients benefit very little. More benefit with proper hydration (6-8 8-ounce glasses of water). |
After placing a patient on initial pharm therapy, when should f/u occur? | 1 month |
What is the flow rate Rx for O2? | Prescribed at a flow rate to produce 90% saturation. |
What is the treatment for this stage? Stage 2: Moderate | • Active reduction of risk factors • Flu vaccine • SABA • 1 or more LABAs • Pulmonary Rehab |
What is the treatment for this stage? Stage 3: Severe | • Active reduction of risk factors • Flu vaccine • SABA • 1 or more LABAs • Pulmonary Rehab • ICS if repeated exacerbations |
T/F Cough suppressants benefit bronchitis patients over emphysema patients. | False. They should be avoided in all. Benefits of expectoration are more important, esp to prevent pneumonia. |
T/F COPD patients should be vaccinated for flu and pneumonia. | True. Vaccinate for influenza (annually) and pneumococcal pneumonia (every 5 years). |
When is O2 therapy recommended? | • Cor pulmonale • Transient (unrelated to exercise) or nocturnal desaturation • Need for exertion-induced dyspnea prophylaxis |
What type of meals are beneficial? | • Small, frequent meals • Nutritional supplements often beneficial in emphysema |
Is postural drainage beneficial for bronchitis or emphysema? | Bronchitis |
How often should the SABA and LABA be used? | • SABA = PRN • LABA = BID |
What are the nonpharm options for COPD? | • Pulmonary Rehab • O2 Therapy • Surgery • Bullectomy • Lung Volume Reduction (severe cases) • Lung Transplant (end-stage) |
What are the goals of COPD treatment? | • Reduce symptoms and improve quality of life • Increase exercise tolerance/maximize lung function • Decrease exacerbations • Prevent disease progression • Smoking cessation • Precipitant avoidance • Infection prevention |
What is the treatment for this stage? Stage 1: Mild | • Active reduction of risk factors • Flu vaccine • SABA |